
DMRA Stock Forecast & Price Target
DMRA Analyst Ratings
Bulls say
Damora Therapeutics is attractive fundamentally because DMR-001 has already entered the clinic, with FDA-cleared IND status and Phase 1 dose-escalation enrolling at multiple U.S. sites, while a Bayesian adaptive design and more than 50 selected global sites could speed dose-finding and expansion. Its preclinical profile is especially compelling: DMR-001 binds both Type 1 and Type 2 mutCALR, showed a mean 95-fold potency improvement across non-Type 1 variants, and offers monthly subcutaneous dosing that may be meaningfully more convenient than competing IV or biweekly approaches. Financially, the company’s $528.5M in cash, cash equivalents, and marketable securities is expected to fund operations into 2H 2029, covering proof-of-concept readouts starting in mid-2027 and planned Phase 3 timing in mid-2028 while DMR-002 and DMR-003 add additional pipeline value.
Bears say
Damora Therapeutics is viewed negatively because its lead program, DMR-001, faces substantial clinical execution risk, including IND submission delays, manufacturing challenges, slower-than-expected enrollment, and the possibility that the mid-2027 Ph 1 POC readout disappoints or fails to show meaningful improvement versus INCA033989. The commercial thesis is also weakened by INCA033989’s 2-3 year head start, which could let a rival capture much of the addressable mutCALR population before Damora can prove durable efficacy or SC Q4W tolerability. More broadly, the target market is difficult because existing MF therapies such as Jakafi and other JAK-based approaches are limited by toxicity, dose reductions, and incomplete effectiveness, making Damora highly dependent on flawless differentiation in a crowded and unforgiving clinical landscape.
This aggregate rating is based on analysts' research of Damora Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
DMRA Analyst Forecast & Price Prediction
Start investing in DMRA
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Damora Therapeutics, Inc. (DMRA) Forecast
DMRA Analyst Forecast & Price Prediction
Start investing in DMRA
Order type
Buy in
Order amount
Est. shares
0 shares